patent

Delhi High Court Revives Nippon Steel Patent Application Rejected After Inventor’s Death

by
Delhi High Court ruling on Japanese high-strength steel patent application

A Strong Message on Proof of Right, Inventor Death, and Corporate Patents

The Delhi High Court has delivered a decisive ruling that reshapes how India’s Patent Office must treat corporate patent filings when an inventor dies.
The judgement restores balance between procedural law and commercial reality.
It also sends a clear warning against rigid and misplaced interpretations of the Patents Act.

In a case involving a Japanese steel major, the Court quashed a Patent Office order that had refused a patent application for high-strength steel technology.
The refusal rested on a narrow reading of “proof of right.”
The High Court rejected that approach outright.

The Dispute at a Glance

The case arose from a patent application filed by a Japanese company for an invention titled high-strength steel sheet and its manufacturing method.
The technology targets advanced industrial use.
It promises stronger, lighter, and more durable steel.

The application named four inventors.
All were employees of the company.
One inventor passed away during the pendency of the application.

That single fact triggered a chain of legal errors.

The Indian Patent Office refused the application.
It claimed the company failed to prove its right to apply for the patent.
According to the Controller, the company needed an assignment deed from the deceased inventor or his legal heirs.

The company challenged the refusal before the Delhi High Court.

Patent Office View: Procedure Over Substance

The Patent Office took a strict position.

It held that:

  • The death of one inventor broke the chain of title.
  • An employment agreement was not enough to establish ownership.
  • A formal assignment was mandatory.
  • Without it, the company lacked legal standing.

The Controller relied heavily on Section 68 of the Patents Act, which governs assignments.
The Office treated the application as legally defective.

This approach placed form above function.
It ignored how corporate innovation actually works.

High Court Pushback: Law Must Serve Logic

The Delhi High Court firmly disagreed.

The Court ruled that the Patent Office misread the law and misapplied statutory provisions.
It quashed the refusal order in full.

The judgment draws a sharp line between:

  • The right to apply for a patent, and
  • The assignment of a granted patent.

The Patent Office, the Court said, wrongly merged the two.

Employment Contracts Matter

At the heart of the ruling lies one critical finding.

The Court held that an employment agreement can constitute valid proof of right under Indian patent law.

The inventor had signed the agreement during his lifetime.
That agreement clearly vested intellectual property rights in the employer.
The inventor’s later death did not undo that transfer.

The Court emphasized that:

  • The right to apply arises at the filing stage.
  • Section 7 of the Patents Act governs this stage.
  • Section 68 applies only after a patent is granted.

By invoking Section 68 prematurely, the Patent Office committed a legal error.

Inventor Death Is Not a Legal Dead End

The ruling delivers clarity on a sensitive issue.

Inventor death does not automatically invalidate a patent application.
Nor does it force companies into impossible compliance.

The Court noted that:

  • The invention was created during employment.
  • Rights already vested in the company.
  • No fresh assignment was legally required.

Requiring legal heirs to execute assignments would create uncertainty.
It would also disrupt global innovation chains.

The Court refused to allow such instability.

Comparative View: India vs Global Practice

The judgment aligns Indian patent law with global norms.

In major innovation jurisdictions:

  • Employment agreements routinely govern IP ownership.
  • Corporate applicants rely on internal policies.
  • Inventor death does not derail filings.

The Delhi High Court recognized this reality.

It implicitly acknowledged that multinational companies cannot chase posthumous paperwork across borders.
Patent systems must support innovation, not sabotage it.

Procedural Law Is a Tool, Not a Weapon

The Court delivered another powerful message.

Procedural law must advance justice.
It must not obstruct it.

The judgment criticized mechanical decision-making.
It warned against turning technical rules into roadblocks.

Patent examiners, the Court said, must adopt a pragmatic and legally sound approach.

This observation carries wide implications.

What the Court Ordered

The High Court:

  • Set aside the Patent Office refusal.
  • Restored the application.
  • Directed a fresh examination on merits.
  • Barred reliance on the flawed proof-of-right objection.

The ruling does not grant the patent outright.
It restores due process.

Why This Judgment Matters

This decision has industry-wide impact.

For Corporates

  • Employment contracts gain legal weight.
  • Filing risks reduce.
  • Cross-border patent strategy becomes safer.

For Patent Professionals

  • Proof-of-right standards gain clarity.
  • Section 7 and Section 68 are clearly separated.
  • Examiner discretion faces judicial limits.

For the Patent Office

  • The ruling sets a binding precedent.
  • Over-technical refusals face greater scrutiny.
  • Legal accuracy becomes non-negotiable.

A Win for Innovation, Not Just One Company

This case is not just about steel.

It is about how India treats innovation.
It is about predictability.
It is about fairness.

The Delhi High Court reaffirmed that India’s patent system must support genuine inventors and rightful applicants.
It must not collapse under procedural rigidity.

Conclusion: A Course Correction for Indian Patent Law

The ruling marks a turning point.

It restores confidence in India’s intellectual property regime.
It reassures global innovators.
It strengthens the rule of law.

Most importantly, it confirms one truth:
Innovation does not die with an inventor.

When rights are lawfully vested, the law must respect them.

Enveric Biosciences Secures Key Patent for Non-Hallucinogenic Mental Health Treatments

by
Enveric Biosciences lab developing psychedelic therapeutics for mental health.

Enveric Biosciences bolsters its position in the booming psychedelic-inspired therapeutics market. The company announces a major intellectual property win. The United States Patent and Trademark Office issues U.S. Patent No. 12,492,179.

This patent covers novel molecules titled “Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives.” Enveric designs these compounds to promote neuroplasticity. They target severe mental health disorders without causing hallucinations.

Patients struggle with depression, anxiety, PTSD, and addiction. Traditional treatments often fail. Enveric’s innovation addresses this gap. The new molecules derive from mescaline-like structures. Scientists modify them chemically. They enhance efficacy. They reduce side effects.

Hallucinogenic psychedelics show promise. Yet they pose challenges. Patients experience intense trips. Clinics require supervision. Regulators demand more data. Enveric avoids these hurdles. Its neuroplastogens deliver brain rewiring benefits. They skip the psychedelic experience.

Joseph Tucker, Ph.D., leads Enveric as CEO. He celebrates the milestone. “This patent expands our portfolio. It strengthens our pipeline. We target disorders with limited options. Our molecules interact with key receptors in novel ways. They promise better safety and outcomes.”

Composition-of-matter patents offer strong protection. They shield the core chemical structures. Enveric attracts partners. Big pharma seeks licensing deals. The company builds a competitive moat.

Enveric focuses on next-generation therapeutics. It develops small-molecule drugs. These promote neuroplasticity – the brain’s ability to form new connections. Neuroplasticity drives recovery in mental illness.

The psychedelic drugs market explodes. Analysts project growth from about $3-4 billion in 2024 to $8-10 billion by 2032. Compound annual rates hit 13-15%. Mental health crises fuel demand. Over 264 million people suffer depression worldwide. Treatment-resistant cases rise.

Companies chase non-hallucinogenic options. Enveric pioneers this shift. Its Psybrary™ platform generates thousands of candidates. Artificial intelligence aids discovery. The company holds dozens of patents. It issues more in 2025.

Enveric’s lead candidate shines. EB-003 advances rapidly. This first-in-class compound engages 5-HT2A and 5-HT1B receptors. It delivers fast antidepressant and anxiolytic effects. Preclinical data impress. Oral bioavailability works well. Brain penetration proves strong.

Enveric targets IND filing soon. Phase 1 trials follow. EB-003 treats outpatient settings. No need for therapists during sessions. Patients take pills at home. Convenience boosts adherence.

Other pipelines progress. EVM301 and EVM401 series expand. Notices of allowance arrive. Patents issue. Enveric licenses non-core assets. It funds core development.

Investors react positively. Shares jump in premarket trading after the December 29 announcement. The stock faces volatility. It trades as a micro-cap. Market cap hovers low. Yet milestones drive gains.

Enveric raises funds. Warrant exercises bring millions. Cash supports trials. The company regains Nasdaq compliance.

Experts praise the approach. Non-hallucinogenic drugs scale easier. They fit existing healthcare systems. Insurers cover standard pills. Clinics avoid psychedelic infrastructure.

Regulators warm to safer profiles. FDA grants breakthrough designations elsewhere. Enveric positions EB-003 for similar status.

Mental health innovation lags. Antidepressants date back decades. Side effects deter patients. Relapse rates stay high. Psychedelic research revives hope. Enveric refines it.

Researchers link neuroplasticity to recovery. Psychedelics boost dendritic growth. They increase synapses. Non-hallucinogenic versions isolate this mechanism.

Enveric collaborates. It presents at conferences. Data publications follow. Peer-reviewed papers validate methods.

Challenges remain. Clinical trials cost dearly. Enveric seeks partners. Out-licensing generates revenue.

The field attracts talent. Investors eye neuroplastogens. Enveric leads with patents and data.

Patients await better options. Suicide rates climb. Addiction devastates families. Enveric aims to help.

This patent marks progress. Enveric executes strategy. It builds value. The future looks brighter for mental health treatment.

Enveric Biosciences trades on Nasdaq as ENVB. It operates from Cambridge. The team drives innovation. They transform lives.

The mental health revolution gains speed. Enveric rides the wave. Non-hallucinogenic therapies emerge. Hope grows.

Sony Unleashes AI Ghostwriter: A New Era of Real-Time Game Censorship

by

Sony Interactive Entertainment has ignited a firestorm in the gaming world. A newly published patent reveals a future where video games change while you play. This technology uses Artificial Intelligence to edit, blur, or even rewrite digital content on the fly. It is called “Automatic Bespoke Edits of Video Content Using AI.” The implications are massive.
The Mechanics of Instant Modification
Sony’s vision sits between the game engine and your screen. It acts like a high-tech filter. The AI scans every frame of video and every second of audio. It looks for “sensitive” material. This includes gore, sexual themes, and profanity.
The system does not just block a game. It remodels it. If the AI detects a violent execution, it might blur the blood. If a character screams a curse word, the AI mutes the sound. Most shockingly, the patent describes using Deepfakes. The system could replace a severed limb with a harmless object. It could swap a frightening monster for a cartoon character. This happens in milliseconds.
Power to the Parents
Sony frames this as the ultimate safety tool. Traditional age ratings are rigid. A “Mature” rating blocks the entire game from a child. This AI allows for a “middle ground.” * Profiles: Parents can set custom rules for each family member.

  • Safety Toggles: Users can choose to hide specific triggers, like spiders or needles.
  • Seamless Flow: The game keeps running. There are no abrupt cuts or “black bars.”
    For many, this is a dream come true. It lets kids experience the mechanics of a hit game without the adult themes. It gives players control over their own comfort.
    The Death of Artistic Integrity?
    However, critics are sounding the alarm. They call it “digital sanitization.” Many games are works of art. Developers choose every pixel for a reason. In titles like The Last of Us, violence serves the story. It makes the world feel dangerous.
    If an AI scrubs away the grit, does the story lose its soul? Some fear that platform holders like Sony will gain too much power. They could dictate what is “acceptable” across all games. This moves the power from the creator to the algorithm.
    A Shadow Over Creativity
    The fear extends to the development phase. If studios know an AI will rewrite their work, they might stop taking risks. They might design games for the “lowest common denominator.” This could lead to a future of bland, corporate-approved content.
    Furthermore, the technology relies on “sentiment analysis.” AI often struggles with context. It might mistake a character’s grief for “negative content.” It might mute a powerful monologue because of a single intense word. This creates a disjointed and confusing experience for the player.
    The Road Ahead
    A patent is not a product. Sony files hundreds of ideas every year. Many never see the light of day. But this patent shows a clear direction. Sony wants the PlayStation ecosystem to be the most adaptable platform on Earth.
    The gaming community is watching closely. The industry stands at a crossroads. One path leads to unparalleled accessibility and safety. The other leads to a world where “The Player’s Experience” is curated by a machine, not a human. Whether this becomes a tool for protection or a weapon for censorship remains to be seen. For now, the line between a “custom experience” and “altered art” has never been thinner.

Crompton Greaves Strikes Gold: New Patent to Revolutionize Smart Cooling

by


Innovation just hit a new high. On December 19, 2025, Crompton Greaves Consumer Electricals Limited (CGCEL) secured a landmark patent. The Indian Patent Office granted patent number 576195 for a breakthrough in energy-efficient cooling. This technology does more than just blow air. It bridges the gap between your ceiling fan and your air conditioner.
This news comes at a perfect time. Only days ago, the President of India honored Crompton with the National Energy Conservation Award 2025. The company is on a winning streak. They are proving that sustainability and high-tech comfort can go hand in hand.
The Innovation: A “Deep Sleep” Revolution
For years, consumers faced a choice. They could freeze under an AC or stay warm with just a fan. Running an AC at 18°C wastes massive amounts of power. Running a fan alone often fails in the scorching Indian heat. Crompton’s new patented system solves this.
The technology uses a retrofit controller device. This device talks to both your fan and your AC. It uses an Infrared (IR) communication protocol to sync them. It doesn’t matter what brand of AC you own. The controller features a 360-degree IR reach and interoperable codes. It works with almost anything.
Key Features of the Patent:

  • Environmental Intelligence: Sensors track temperature and humidity in real-time.
  • The Deep Sleep Algorithm: This software adjusts fan speeds and AC settings automatically. It ensures uniform cooling across the entire room.
  • OTA Updates: The system stays smart. It receives “Over-the-Air” updates to improve performance over time.
  • Universal Compatibility: It controls ceiling fan status and speed either locally or wirelessly.
    Power Words: Efficiency, Savings, and Comfort
    Crompton is not just selling a gadget. They are selling a “Greener Future.” By using a fan to circulate AC air more effectively, users can set their ACs to a higher, more efficient temperature (like 26°C). This simple shift can slash electricity bills.
    The company’s ActivBLDC motor technology already saves up to 50% on fan energy. Now, by optimizing the AC—the biggest energy hog in most homes—Crompton is targeting the heart of household expenses.
    Market Impact: Crompton 2.0
    This patent is a pillar of the “Crompton 2.0” strategy. Managed by CEO Promeet Ghosh, this vision focuses on premium products and consumer-centric innovation. The goal is clear: double the company’s turnover in the next five to six years.
    Investors are watching closely. While the stock has seen volatility this year, analysts remain bullish. The patent reinforces Crompton’s moat against competitors. It transforms a standard fan manufacturer into a “Smart Climate” leader.
    | Metric | Details |
    |—|—|
    | Patent Number | 576195 |
    | Grant Date | December 19, 2025 |
    | Validity | 20 Years |
    | Strategic Goal | Cross $1 Billion in Sales |
    Looking Ahead
    The climate is changing, and so is the way we cool our homes. Crompton’s new patent promises a world where your appliances think for you. No more waking up at 3:00 AM because the room is too cold. No more “bill shock” at the end of the month.
    Crompton Greaves is no longer just a household name. With this patent, they are the architects of the modern, energy-conscious Indian home.

Tesla’s Secret Weapon: The Invisible Starlink Shield

by


Tesla is rewriting the rules of connectivity. A bombshell patent filing reveals a future where dead zones vanish. Elon Musk is merging his two greatest empires: Tesla and SpaceX. The goal is simple. Total global dominance through satellite-integrated vehicles.
For years, drivers faced a digital wall. Metal car roofs act like cages. They block signals. They kill high-speed data. Tesla’s new patent, published on December 4, 2025, shatters that wall. It introduces a revolutionary “Radio Frequency Transparent” roof. This is not just a sunroof. It is a gateway to the stars.
The Death of the Dead Zone
Connectivity is the lifeblood of the modern electric vehicle. Tesla relies on data. It needs data for Autopilot. It needs data for over-the-air updates. It needs data for the massive screens inside the cabin. Today, that data comes from cellular towers.
But towers have limits. They fail in mountains. They disappear in deserts. They collapse during natural disasters. This is a fatal flaw for a self-driving future. A Robotaxi cannot lose its mind in a tunnel or a rural valley. It must stay awake. It must stay connected.
Tesla’s solution is the Starlink antenna. By burying these receivers directly into the car’s roof, Tesla creates a permanent link to the SpaceX constellation. This is “always-on” internet. It works in the middle of a hurricane. It works in the heart of the Sahara.
The Engineering Miracle: Hidden in Plain Sight
Traditional satellite dishes are ugly. They are bulky. They ruin aerodynamics. Tesla refuses to sacrifice style. The new patent describes a multi-layered sandwich of high-tech polymers.
Engineers are using Polycarbonate (PC) and Acrylonitrile Styrene Acrylate (ASA). These are not standard plastics. These materials offer the strength of steel. They offer the clarity of glass. Crucially, they allow radio waves to pass through like ghosts.
The antenna sits beneath this skin. It is invisible to the eye. It is perfectly aerodynamic. It adds zero drag. This engineering feat allows Tesla to maintain its sleek, futuristic silhouette while housing the most powerful communication tool on Earth.
Powering the Robotaxi Revolution
Why does this matter now? The answer is autonomy. Tesla is betting everything on the Robotaxi. These autonomous fleets require massive bandwidth. They need real-time HD maps. They need constant communication with a central command.
A cellular glitch could paralyze an autonomous fleet. Starlink removes that risk. It provides a redundant, high-speed backbone. If the 5G network fails, the car switches to space. This seamless handoff ensures safety. It ensures reliability. It makes Tesla the only car company capable of operating truly anywhere.
An Entertainment Powerhouse
The benefits aren’t just for the computers. They are for the humans inside. As cars become mobile lounges, passengers want more. They want 4K streaming. They want lag-free gaming. They want high-fidelity video calls.
Current LTE and 5G connections often throttle during peak hours. Starlink does not. With a direct-to-satellite link, every Tesla becomes a rolling high-speed office. It becomes a theater on wheels. This transforms the commute. It turns a boring drive into a productive or entertaining experience. This is a massive competitive edge. Other manufacturers are tethered to the ground. Tesla is tethered to the heavens.
The Musk Synergy: A Vertical Empire
No other automaker can do this. Ford cannot build its own satellite network. Toyota cannot launch rockets. Elon Musk owns the infrastructure of the future.
SpaceX has already launched thousands of Starlink satellites. They are already testing “Direct-to-Cell” technology. The “STARLINK MOBILE” trademark is already active. This patent is the final piece of the puzzle. It creates a closed-loop ecosystem.
Tesla builds the car. SpaceX provides the internet. The customer gets an unparalleled experience. The revenue stays within the Musk empire. It is a masterstroke of vertical integration. It creates a barrier to entry that legacy carmakers cannot overcome.
Breaking the Regulatory Chains
Tesla currently faces intense scrutiny. Regulators in California are questioning “Full Self-Driving” claims. Market competition is fierce. Sales have fluctuated. Tesla needs a “wow” factor.
This satellite integration is that factor. It moves the goalposts. It shifts the conversation from battery range to digital capability. In the 20th century, horsepower was king. In the 21st century, data is the crown. Tesla is hoarding that data.
The Global Impact
This technology has massive implications for global safety. Imagine a Tesla in a remote area during a wildfire. The driver needs evacuation routes. The cell towers are burned out. The Tesla remains online. It receives emergency broadcasts. It guides the family to safety via satellite.
Imagine a scientist in the Arctic. Imagine a doctor in a developing nation. This technology brings the world closer. It democratizes information. It proves that the car is no longer just a mode of transport. It is a tool for survival and connection.
The Competition is Scrambling
Rivian and Lucid are watching. They are trying to catch up on battery tech. But they are lightyears behind on connectivity. While they negotiate with telecom giants, Tesla is building its own sky.
The industry is at a crossroads. Some companies will remain “dumb” cars with big batteries. Tesla is becoming a “smart” node in a global mesh network. The gap is widening. The “Invisible Starlink Shield” is more than a patent. It is a declaration of war against the status quo.
Looking Ahead: 2026 and Beyond
Production of the RF-transparent roof could begin soon. Reports suggest the Cybertruck or the upcoming “Model 2” might be the first to feature this tech. If successful, it will become standard across the fleet.
The world is changing. The sky is no longer the limit; it is the source. Tesla’s patent is a bold step into the unknown. It promises a world where you are never lost. A world where you are never offline. A world where your car is your most powerful connection to the rest of humanity.
Elon Musk promised the future. With this patent, he is delivering it—one satellite beam at a time. The era of the truly connected car has arrived.

Madras High Court Crushes Intra-Court Appeals in Patent Disputes

by
A professional legal graphic featuring the Madras High Court building in the background with a wooden gavel and law books in the foreground. A gold-embossed plaque reads "Madras High Court Patent Appeal Ruling," symbolizing the finality of the court's decision.

In a landmark ruling that reshapes the procedural landscape of intellectual property litigation in India, the Madras High Court has declared that no intra-court appeal (Letters Patent Appeal) can be entertained against a Single Judge’s decision when that judge is exercising appellate jurisdiction under the Patents Act, 1970.

The decision, delivered in the case of Italfarmaco S.p.A. v. Deputy Controller of Patents and Designs, effectively closes a long-debated procedural loophole and brings the Madras High Court in line with the Delhi High Court, ensuring a more uniform approach to patent disputes across India’s major commercial hubs.

The Legal Dispute: A Question of Procedure

The case reached the Division Bench of the Madras High Court after Italfarmaco S.p.A., an Italian pharmaceutical major, sought to challenge a Single Judge’s order that had upheld the Patent Office’s rejection of their patent application.

The central question was whether a litigant, dissatisfied with an order passed by a Single Judge in a patent appeal, could approach a two-judge (Division) bench of the same High Court under the “Letters Patent” (the founding charters of the High Courts).

Historically, “Letters Patent Appeals” (LPAs) have served as an internal mechanism for correcting errors by Single Judges. However, the Patent Office and the Deputy Controller argued that once the Intellectual Property Appellate Board (IPAB) was abolished in 2021, and its powers transferred to the High Courts, the specialized nature of the Patents Act superseded the general internal rules of the Court.

The Court’s Reasoning: A “Special Law” Precedent

The Division Bench’s judgment rests on three critical pillars of Indian law:

1. The Patents Act as a Self-Contained Code

The court emphasized that the Patents Act, 1970, is an exhaustive and specialized statute. Section 117A of the Act explicitly lists which orders of the Controller are appealable. The Court noted that the legislature chose not to include a provision for a “Second Appeal” within the High Court. By failing to provide for such an appeal, the legislature intended for the Single Judge’s appellate decision to be final within the High Court system.

2. The Impact of the Tribunals Reforms Act, 2021

Until 2021, appeals against the Patent Office were heard by the IPAB. When the IPAB was abolished, its jurisdiction was transferred to the High Courts. The Madras High Court reasoned that since there was no intra-board appeal within the IPAB, there should not be a “bonus” layer of appeal just because the jurisdiction shifted to the High Court. The High Court, in this context, is merely stepping into the shoes of the defunct tribunal.

3. Restraints of the Commercial Courts Act, 2015

The Court also highlighted Section 13(1A) of the Commercial Courts Act. This Act, which governs patent disputes as “commercial disputes,” strictly limits appeals. It mandates that an appeal shall lie only from those orders specifically enumerated in Order XLIII of the Code of Civil Procedure (CPC). Since a Single Judge’s judgment on a patent appeal is not among those listed, the Division Bench concluded it lacked the statutory authority to hear the case.

Comparison: The New Litigation Roadmap

Before this ruling, the “maintainability” of intra-court appeals in patent matters was a gray area, often leading to years of procedural delays. The following table illustrates the streamlined process following the Italfarmaco decision:

Procedure PhasePrevious Practice (Uncertain)New Legal Standard (Madras HC)
Originating OfficeIndian Patent Office (Controller)Indian Patent Office (Controller)
First AppealSingle Judge (High Court)Single Judge (High Court)
Second AppealLetters Patent Appeal (Division Bench)PROHIBITED
Highest RecourseSupreme Court of IndiaSupreme Court of India (SLP)

Industry Impact: Faster Resolution vs. Limited Recourse

Legal experts and stakeholders in the pharmaceutical and tech sectors are viewing the judgment with a mix of relief and caution.

  • Expedited Timelines: By removing one layer of litigation, the “life cycle” of a patent dispute is reduced by several years. This is crucial in sectors like electronics or pharmaceuticals, where the commercial value of an invention can diminish rapidly.
  • The “All-or-Nothing” Single Judge Round: For patent applicants, the stakes at the Single Judge level are now significantly higher. Attorneys must now treat the first appeal as their final opportunity to present technical evidence and legal arguments within the High Court.
  • National Uniformity: This ruling mirrors the stance of the Delhi High Court. For multinational corporations, this uniformity reduces “forum shopping” (choosing a court based on favorable procedural rules) and provides a predictable legal environment.

Conclusion: The Road to the Supreme Court

The Madras High Court’s ruling effectively marks the end of “internal” litigation for patent rejections. Litigants who fail to convince a Single Judge now have only one door left open: a Special Leave Petition (SLP) under Article 136 to the Supreme Court of India.

While the Supreme Court is notoriously selective in the cases it hears, this ruling ensures that only the most significant questions of law—rather than routine factual disputes—will ascend to the country’s highest court. For the Indian patent system, this move signifies a shift toward maturity, prioritizing the speed of innovation over the length of litigation.

Safe Pro Group (SPAI) Files New AI Patent for Drone-Based Threat Detection

by
AI computer vision interface showing autonomous detection and labeling of explosive threats from a high-altitude drone perspective.

As the global reliance on Unmanned Aerial Systems (UAS) transitions from simple reconnaissance to complex, high-stakes decision-making, the bottleneck has remained the same: the human ability to process vast amounts of visual data accurately and in real-time. Addressing this critical gap, Safe Pro Group Inc. (NASDAQ: SPAI), a leader in AI-driven security and survival solutions, recently announced the filing of a groundbreaking patent application that promises to redefine the standards of computer vision in drone-based operations.

The new patent, titled “Object Detection Precision Enhancement Methods, Tools and Systems,” introduces a sophisticated algorithm specifically designed to enhance the detection of minute, high-risk objects within expansive datasets. This development marks a significant milestone for the company’s intellectual property (IP) portfolio and signals a paradigm shift for industries ranging from humanitarian demining to national defense.

The Challenge of the “Small Object” Problem

In the world of computer vision, “small object detection” is a notorious technical hurdle. When a drone flies at a high altitude to cover more ground, a landmine or an unexploded ordnance (UXO) may only occupy a few pixels on a 4K image. Standard AI models often struggle with these “needle in a haystack” scenarios, frequently resulting in false negatives (missed threats) or overwhelming false positives that paralyze operations.

Safe Pro’s new algorithm directly addresses this by utilizing a novel approach to image analysis. By refining how the AI interprets geospatial data and high-resolution imagery, the technology can maintain extreme precision even when processing massive datasets at high speeds. This capability is not merely a theoretical improvement; it is a necessity for “wide-area” operations where thousands of hectares must be cleared of threats to ensure human safety.

SpotlightAI™ and the Future of Demining

At the heart of Safe Pro’s technological ecosystem is SpotlightAI™, a platform that transforms standard drone imagery into actionable intelligence. The company’s newly filed patent acts as an “engine upgrade” for this platform.

The effectiveness of this technology has already been demonstrated in one of the world’s most challenging environments: Ukraine. Recent reports indicate that Safe Pro’s AI has delivered an 800% surge in productivity for demining surveys. By automating the identification of explosives, the system allows human demining teams to focus their efforts on confirmed danger zones, significantly reducing the time and risk involved in land clearance.

To date, Safe Pro’s unique datasets—which include over 2.2 million drone images and more than 41,400 identified threats across 28,000 acres—provide a “real-world” training ground that few competitors can match. This data-driven approach ensures that the algorithm is battle-tested and optimized for the chaotic visual environments of active conflict zones and post-war reconstruction sites.

Strategic Integration with the U.S. Military

The filing of this patent comes at a strategic time as Safe Pro deepens its relationship with the U.S. Department of Defense. The company has confirmed it will showcase these enhanced AI capabilities during several high-profile events with the U.S. Army throughout 2026.

Key demonstrations will include:

  • The Concept Focused Warfighter Experiment (CFWE): A venue for testing cutting-edge tech in simulated combat scenarios.
  • The Live Breach Event: Where the AI’s ability to detect obstacles and explosives in real-time will be put to the test.
  • CFWE Maneuver (CFWE-M): A demonstration focusing on how autonomous detection can support troop movement and battlefield awareness.

By securing the IP for these “Precision Enhancement” methods, Safe Pro is positioning itself as a vital contractor for modern “mosaic warfare,” where distributed drone networks provide the primary eyes for ground commanders.

A Growing Global IP Fortress

This latest filing is a continuation of Safe Pro’s aggressive strategy to protect its technological moat. The company already holds US Patent No. 12,146,729, which covers the autonomous detection, identification, and labeling of explosives in orthomosaic images. Valid until 2043, this foundational patent establishes Safe Pro as a primary gatekeeper of AI-driven explosive detection.

Furthermore, Safe Pro is expanding its reach far beyond U.S. borders. The company has entered the “national phase” of its international applications under the Patent Cooperation Treaty (PCT). This includes seeking protection in 47 jurisdictions, including the European Union, Canada, Australia, Japan, Israel, and Ukraine.

“Protecting our innovations through a robust international IP strategy is paramount,” the company noted in its disclosure. “Whether deployed on the ‘edge’ via SpotlightAI™ OnSite for real-time analysis or leveraging the cloud via Amazon Web Services (AWS), our technology is built to scale globally.”

Commercial and Humanitarian Implications

While defense applications often capture headlines, the commercial and humanitarian implications of this patent are equally profound. In the agricultural sector, the same “small object detection” precision can be used to identify specific crop pests or early signs of disease from the air, long before they are visible to the naked eye.

In humanitarian terms, the technology offers a path toward a “mine-free world.” By lowering the cost and increasing the speed of landmine detection, Safe Pro’s AI can help return agricultural land to farmers and safe paths to school children in post-conflict nations. The ability to distinguish between a rusted soda can and a lethal anti-personnel mine with high confidence is the “holy grail” of demining—and Safe Pro’s new patent suggests they are closer than ever to achieving it.

Market Outlook and Investor Sentiment

The market has taken notice of Safe Pro’s momentum. Despite the inherent volatility in the tech and defense sectors, the company’s steady accumulation of IP and its $14 million in recent funding from partners like Ondas Holdings Inc. suggest strong institutional confidence.

Investors are increasingly looking for “AI-plus” companies—those that don’t just develop software, but apply it to tangible, high-barrier-to-entry physical problems. Safe Pro Group fits this description perfectly, combining sophisticated machine learning with the rugged requirements of field security and explosive ordnance disposal (EOD).

Conclusion

The filing of the “Object Detection Precision Enhancement” patent is more than just a legal formality; it is a statement of intent. By solving the technical limitations of drone-based computer vision, Safe Pro Group is making the world safer, one pixel at a time.

As the company prepares for its 2026 demonstrations with the U.S. Army, the focus will remain on the transition from “seeing” to “understanding.” In the high-stakes environments where Safe Pro operates, the difference between a successful mission and a tragedy often comes down to the speed and accuracy of an algorithm. With this new patent, Safe Pro Group has ensured that its AI will remain at the forefront of that life-saving frontier.

About Safe Pro Group Inc.

Safe Pro Group Inc. is a US-based provider of safety and survival solutions for military, law enforcement, and humanitarian organizations. Their SpotlightAI™ platform represents the cutting edge of autonomous threat detection, leveraging massive geospatial datasets to identify risks in complex environments.

MDU Rohtak Patent: Laser-Free Tech Cuts Osmotic Tablet Cost

by
A detailed, realistic 3D render of a pharmaceutical manufacturing process. A stainless steel tablet compression machine with specialized notched tooling is actively drilling precise central holes into white, round osmotic tablets moving along a green conveyor belt. A plaque on the machine reads: "MDU Rohtak - Notched Tooling Tech," "Patent Granted," and lists the inventors: "K.S. Tiwari, M. Garg, Guided by H. Dureja." The background shows blurred laboratory glassware on shelves, signifying a research environment.

Maharshi Dayanand University (MDU) scientists achieved a major breakthrough. They secured a design patent for a new tablet manufacturing technique. This innovation directly affects the production of high-tech osmotic tablets.

New Tooling Cuts Production Costs

The MDU Pharmaceutical Sciences Department developed the technology. It uses notched tooling for standard tablet compression machines. This new tool creates the necessary hole in the tablet. The hole allows for controlled, constant drug release.

“This is a game-changer,” said a university spokesperson.

Expensive Lasers Become Obsolete

The pharmaceutical industry currently uses expensive laser drilling to create this orifice. This specialized step adds significant cost and time. The MDU team bypasses this costly process entirely.

Their notched tooling creates the precise hole during compression. This single-step method eliminates the need for extra laser equipment.

Faster, Cheaper Medication Delivery

The patented technology offers clear benefits:

  • Cost Reduction: Manufacturers save money on expensive machinery.
  • Time Savings: The process integrates drilling into the main production line.
  • Affordability: Reduced production costs can make complex drugs cheaper for patients.

Osmotic tablets treat chronic conditions. These include hypertension, diabetes, and ADHD. They rely on the small hole to deliver medication over many hours. This technology makes controlled-release dosage forms more accessible.

The team included Kirpa Shankar Tiwari, Professor Munish Garg, and Professor Harish Dureja. MDU’s research now promises to revolutionize the efficiency of tablet manufacturing worldwide.

COURT CLEARS SUN PHARMA TO EXPORT KEY WEIGHT LOSS DRUG; RESTRICTS INDIA SALE

by
Delhi High Court ruling in Sun Pharma versus Novo Nordisk patent dispute over the semaglutide drug (Ozempic/Wegovy) formulation.

The Delhi High Court today delivered a split verdict. It allowed Sun Pharmaceutical Industries to manufacture and export its version of the blockbuster drug semaglutide. However, the court strictly barred the company from selling the product in the domestic Indian market.

Court Upholds Patent Expiry Timeline

The decision is a major development in the pharmaceutical patent battle. Danish giant Novo Nordisk markets semaglutide globally. It is the active ingredient in its widely-used diabetes and weight-loss drugs, Ozempic and Wegovy.

Novo Nordisk sued Sun Pharma for patent infringement. The Danish company seeks to protect its secondary patent. This patent covers specific formulations and the delivery system of the drug. The patent remains valid until March 2026.

The court’s ruling respects this expiration date. It ordered Sun Pharma to refrain from all sales within India until the patent lapses.

Exports Allowed: A Win for Generics

Crucially, the court granted Sun Pharma permission to continue manufacturing. It also allowed exports to countries where Novo Nordisk does not hold patent protection.

This order mirrors a recent ruling against Dr. Reddy’s Laboratories (DRL). Justice Manmeet Pritam Singh Arora heard both cases. She had previously allowed DRL similar manufacturing and export rights.

Sun Pharma provided a formal undertaking to the court. The company will comply with the domestic sales ban. It will also provide the court with full details of its manufacturing and export accounts.

Evergreening Challenge Cited

The ongoing dispute centers on the validity of Novo Nordisk’s secondary patent. Generic makers argue the patent constitutes evergreening.

Evergreening is a common practice. Companies attempt to extend their patent monopoly. They secure new patents on minor modifications to an existing drug.

The Indian Patents Act, specifically Section 3(d), prohibits this. This section denies patents for new forms of a known substance. The new form must show a significant enhancement in therapeutic efficacy.

The court noted that Sun Pharma and DRL raised a “credible challenge” to the secondary patent’s validity. This legal challenge bolstered the generic companies’ position.

Market Impact: A Race for 2026

The ruling is a clear signal. It encourages Indian generic companies to prepare for market entry.

The global market for GLP-1 drugs like semaglutide is massive. Indian drug makers are now lining up to launch their generic versions.

The ban on domestic sales protects Novo Nordisk’s current market exclusivity. Yet, the export green light allows generic firms to gain a foothold. This prepares them for a competitive domestic launch in March 2026.

Novo Nordisk still holds an advantage in the Indian market. It recently cut the price of its product, Wegovy. This move increases competition against rivals like Eli Lilly’s Mounjaro.

Novo Nordisk has indicated it intends to appeal the court’s earlier decision in the DRL case. The legal battle for the lucrative weight-loss drug market will continue.

Korea Neuromorphic Chip Patent Growth: Secures Global Second Spot

by
diagram of a neuromorphic chip architecture mimicking the human brain

South Korea secured a significant global ranking. The nation stands second worldwide in neuromorphic chip patent growth. These chips are crucial for the next generation of artificial intelligence.

PATENT GROWTH EXPLODES

Korea’s growth rate reached 39.1%. This spans a 22-year period. Officials analyzed data from 2003 to 2024. This growth places Korea right behind China. China’s growth rate was 39.3%. The United States, China, the EU, and Japan also submitted data. These nations form the IP5 group.

Korea also boasts high application volume. It ranks third globally in total applications. The nation filed 702 patents. The US leads the world with 1,528 filings. China holds second place with 839 applications.

KOREAN FIRMS DOMINATE TOP 10

Korean corporations show strong technological leadership. Four institutions appear in the global top 10 list.

  • Samsung Electronics ranks highest. It secured the third overall spot. The firm filed 183 patents.
  • The Electronics and Telecommunications Research Institute (ETRI) followed. It holds the sixth position with 85 filings.
  • SK hynix came in seventh. It filed 84 applications.
  • Seoul National University also made the list. The university ranked ninth with 56 filings.

Globally, IBM and Qualcomm led the individual applicant rankings.

CHIPS MIMIC THE HUMAN BRAIN

Neuromorphic semiconductors mimic the human brain. They copy the brain’s neural network structure. This design allows for computations with lower power consumption. They use less power than traditional methods.

Experts expect wide adoption of the technology. Key application fields include Autonomous Driving and intelligent robots. They will also impact biometric recognition and medical diagnostics.

The market is set for massive growth. Last year, the market value was $28.5 million. Analysts project huge expansion by 2030. They forecast a market size of $1.3252 billion. This reflects an average annual growth rate of 89.7%.